=), previous ASCT, organ dysfunction, or active infection will receive regimen 2-1 or 2-2.(Mainly, regimen 2-1 will be selected in patients with lymphoid malignancy and regimen 2-2 will be selected in
Sponsors
Division of Hematology, Saitama Medical Center, Jichi Medical University
Conditions
High-risk advanced hematological disease(leukemia and malignant lymphoma in non-remission, MDS with more than 20% of blast, and relapsed disease after allogeneic transplantation)Standard-risk advanced hematological disease(leukemia and malignant lymphoma in remission, MDS, IMF, and SAA)
Unknown Phase
HLA-mismatched allogeneic hematopoietic stem cell transplantation for standard-risk advanced hematological disease using low-dose alemtuzumab
Active, not recruitingJPRN-UMIN000018283
Start: 2015-07-14Target: 23Updated: 2026-06-29
HLA-mismatched allogeneic hematopoietic stem cell transplantation for high-risk advanced hematological disease with the adjustments of immunosuppressants and low-dose alemtuzumab.
Active, not recruitingJPRN-UMIN000018298
Start: 2015-07-14Target: 28Updated: 2026-06-29